The Use of Protease Inhibitors in Pregnancy: Maternal and Fetal Considerations

Duryea, Elaine L.; Nicholson, Fiona; Cooper, Sara J.; Roberts, Scott W.; Rogers, Vanessa; McIntire, Donald D.; Sheffield, Jeanne S.; Stewart, Robert D.

doi:10.1155/2015/563727

Cited by 11 publications

(9 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 83 HIV-positive women should be advised to commence highly active antiretroviral therapy, deliver by cesarean section (CS) and avoid breast-feeding, whereas HCV-positive women should start appropriate therapy so as to eliminate HCV RNA. 84 …”

Section: Prepregnancy Planningmentioning

confidence: 99%

Pregnancy in women with thalassemia: challenges and solutions

Petrakos

Andriopoulos

Tsironi

2016

IJWH

View full text Add to dashboard Cite

Advances in treatment of thalassemia have led to the aging of thalassemic patients, and consequently concern about successful reproductive outcome is augmented. Although women with thalassemia intermedia only were considered competent of achieving pregnancy, case series reveal the willingness of both thalassemia major and thalassemia intermedia women to have a family. Pregnancy in general is characterized by dynamic multiple-system changes and increased susceptibility to oxidative stress, while homozygous, transfusion-dependent, β-thalassemia patients manifest cardiac, hepatic, endocrine, and metabolic disorders attributable to chronic anoxia and iron overload and thalassemia intermedia, usually nontransfused, is associated with augmented risk of thromboembolic events. Pregnancy in thalassemia should be considered a high risk for both mother and fetus, and favorable outcomes are the result of continuous preconception, antenatal, and postpartum assessment and management by a team of thalassemia experts.

show abstract

Section: Prepregnancy Planningmentioning

confidence: 99%

Pregnancy in women with thalassemia: challenges and solutions

Petrakos

Andriopoulos

Tsironi

2016

IJWH

View full text Add to dashboard Cite

show abstract

“…The disorder of these biological processes within the cell can affect the entire system, causing the cells to fail to function. It has also been reported that the disorders of these biological processes leads to growth retardation and pathological pregnancies resulting in fetal mortality (Dodson, Rozance, et al, 2013;Zubor, Kajo, et al, 2014;Duryea, Nicholson, et al, 2015). In our study, the number of offspring in groups of infected males and females was small compared to other groups, which may be due to changes made on placental proteins.…”

Section: Effects Of Chronic Tgondii Infection On Number Ofmentioning

confidence: 45%

The Effects of Toxoplasma Gondii Infections on Anxiety, Depression and Learning in Offsprings of Infected Parents

Ayaz¹,

Orallar²,

Yaman³

et al. 2019

NWSA

View full text Add to dashboard Cite

Toxoplasma Gondii is a zoonotic parasite showing intracellular localization. Although it doesn't select a specific region in the brain tissue, the cyst forms occurring in the chronic phase may cause behavioral changes when it is located in the brain regions related to behavior. The aim of this study is to investigate whether there is a relationship between neurodegenerative and neuropsychiatric diseases caused by antibodies transmitted to the first generation of T.Gondii infection by behavioral tests. In this study, using a total of 24 female and 6 male rats. Behavioral tests have been applied to F1 generation groups female and male. In this study, female rats with chronic T.Gondii infection have been found to have increased anxiety in open field in the first generation male offsprings and decreased locomotor activity. Increased mobility in male offsprings has been observed in the elevated plus maze test. In female offspring, it has reduced anxiety and depression.

show abstract

“…We were underpowered to detect a significant difference in individual adverse outcomes, but we observed an anticipated percentage of singleton infants affected by PTD, LBW, SGA, and perinatal HIV infection based on previous observational studies of US women with HIV. 3,[8][9][10]13,20,24,25 We made several unexpected observations during this study. Detailed descriptions of ARVs prescribed during pregnancy were recorded for only 30% of the mother-infant pairs in eHARS.…”

Section: Discussionmentioning

confidence: 81%

Impact of Integrase Strand Transfer Inhibitor Use During Pregnancy on Viral Suppression at Delivery and Infant Outcomes: A Statewide Retrospective Cohort Study

Latham

Nissim

Spitznagel

et al. 2022

JAIDS Journal of Acquired Immune Deficiency Syndromes

View full text Add to dashboard Cite

Background:We sought to determine whether pregnant women with HIV prescribed integrase strand transfer inhibitor (INSTI) were more likely to have viral suppression at delivery and any increased risk of adverse infant outcomes.Methods: This was a retrospective, statewide cohort study of women with HIV and their HIV-exposed infants who delivered in South Carolina from 2008 to 2019. Women's antenatal AVRs were classified as INSTI or non-INSTI. We compared the percentage of women with undetectable HIV RNA viral load (,40 copies/mL) at delivery between groups. We compared the percentage of HIVexposed singleton infants who were born preterm delivery, low birth weight, and small for gestational age and had confirmed perinatal HIV infection. Categorical outcomes were compared using the x 2 test or Fischer exact test.Results: A total of 832 infants, including 11 sets of twins, were exposed to maternal HIV. Detailed antiretroviral regimens were available for analysis in a third of mother-infant pairs (n = 315). Half of the infants were exposed to INSTI (159) and half to non-INSTI antiretrovirals (156). Most women had an undetectable viral load at delivery (80% INSTI and 73% non-INSTI, P= 0.11). The percentage of singleton infants with adverse outcomes was similar between INSTI and non-INSTI groups: preterm delivery (21% and 16%, P = 0.3), low birth weight (19% and 21%, P = 0.7), small for gestational age (11% vs 9%, P = 0.5), and perinatal HIV infection (2.5% and 1.3%, P = 0.7). Conclusions:We observed that viral suppression before delivery was similar between pregnant women prescribed INSTI and non-INSTI antiretroviral therapy. The percentage of infants with adverse outcomes was similar when exposed to INSTI and non-INSTI antiretroviral therapy.

show abstract

The Use of Protease Inhibitors in Pregnancy: Maternal and Fetal Considerations

Cited by 11 publications

References 18 publications

Pregnancy in women with thalassemia: challenges and solutions

Pregnancy in women with thalassemia: challenges and solutions

The Effects of Toxoplasma Gondii Infections on Anxiety, Depression and Learning in Offsprings of Infected Parents

Impact of Integrase Strand Transfer Inhibitor Use During Pregnancy on Viral Suppression at Delivery and Infant Outcomes: A Statewide Retrospective Cohort Study

Contact Info

Product

Resources

About